We previously reported a patient who had developed 2 glioblastomas at the age of 54 and 64 years, respectively. The first glioblastoma in the right frontal lobe was treated with surgery and radiotherapy. Ten years later, the patient developed a second, left frontal glioblastoma. Discordant patterns of TP53 and PTEN mutations suggested that the second tumor was not a recurrence but an independently developed glioblastoma. To determine the molecular mechanism underlying this enigmatic case with 10-year survival, we performed whole-exome sequencing. We found that both tumors were IDH-wildtype, excluding the possibility of secondary glioblastomas that developed from a less malignant astrocytic precursor lesion. We here report that the patient carried a heterozygous germline mutation [c.3305_3306insT; p.1102-fs-insT(Gly1105/TrpfsX3)] in the MSH6 mismatch repair gene. Further sequencing revealed that in addition to the germline MSH6 mutation, the first glioblastoma showed loss of the MSH6 wild-type allele, and the second glioblastoma carried a somatic MSH6 mutation [c.1403G>A; p.Arg468His]. Our results indicate that both glioblastomas had 2 hits in the MSH6 gene, and that loss of MSH6 function was the key event in the pathogenesis of these 2 independent primary glioblastomas.
INTRODUCTION
In 2001, we reported on a patient who had developed 2 glioblastomas at the age of 54 and 64 years, respectively (1) . The second glioblastoma had developed 10 years after the first, which had been surgically resected and treated with radiotherapy. Both glioblastomas carried multiple mutations in the TP53 and PTEN genes, but none of these mutations was shared by the 2 lesions, suggesting that the second glioblastoma was not a recurrence of the first, but rather an independently developed primary glioblastoma (1) . The development of 2 independent glioblastomas and the presence of multiple TP53 and PTEN mutations in both lesions suggested genetic instability as a possible underlying cause.
Glioblastomas are the most malignant and most common central nervous system tumors. The survival of the vast majority of glioblastoma patients is very poor, with the median overall survival being 14-16 months, even with current standard radio-chemotherapy with temozolomide (TMZ) (2-4), which was not yet available when our patient developed the first tumor. Thus, the 10-year survival of our patient is extremely rare, as is the development of a second glioblastoma. Now, 16 years after our initial report, we have revisited this clinically unusual case to elucidate its underlying molecular mechanism. Through whole-exome sequencing using archival tissue samples, we have demonstrated that this patient carries a germline mutation in MSH6, one of the DNA mismatch repair genes.
MATERIALS AND METHODS

Patient History
The patient history has been reported previously (1) . Briefly, a 54-year-old man presented with headache of 3-4 months duration and temporal memory loss. Computed tomography (CT) revealed a large tumor in the right frontal lobe, which was slightly enhanced by contrast medium. The patient underwent surgical resection followed by radiotherapy (56 Gy) without chemotherapy. Histologically, the tumor showed marked nuclear atypia, brisk mitotic activity, microvascular proliferation and necrosis, and was diagnosed as glioblastoma (WHO grade IV). Follow-up imaging by CT or magnetic resonance imaging (MRI) was performed every 1-2 years, and revealed no significant change over a period of 9 years.
Ten years after the first operation, the patient presented with memory loss, psychic changes, and aphasia. MRI showed a large tumor, predominantly in the left frontal lobe, with extension into the corpus callosum, contrast enhancement, central necrosis, and perifocal edema. Surgery was performed and the tumor was diagnosed as glioblastoma with a significant fraction of neoplastic gemistocytes. The discordant patterns of TP53 and PTEN mutations in the first and second glioblastomas suggested that the second glioblastoma was not a recurrence but rather an independently developed second primary glioblastoma (1) . The patient died 3 days after the second surgery, due to intracranial hemorrhage. At autopsy, no other neoplasms were detected.
According to the database of the Finnish Cancer Registry, the patient's father was diagnosed with prostate cancer at the age of 76 years. The patient's 3 children (aged 51-55 years) are healthy. Of the patient's 9 siblings, 1 brother was diagnosed with lung cancer at the age of 75 years and 1 sister with breast cancer (ductal carcinoma in situ) at 60 years. No cancers have been reported in any of the patient's 13 nieces and nephews (aged 37-61 years). 
Ethics Statement
Screening for IDH Mutations in Glioblastomas
To assess the IDH status, we carried out Sanger sequencing in 2 glioblastomas of this patient. Sequence of primers and protocol of sequencing have been previously reported (5, 6) .
Exome Sequencing
DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) blocks containing biopsy and autopsy samples of the second glioblastoma and normal liver tissue from the patient, using a standard phenol-chloroform method (7) . The quality and quantity of the extracted DNA was measured using NanoDrop and Qubit (Thermo Scientific, Waltham, MA), as well as TapeStation (Agilent Technologies, Santa Clara, CA). DNA libraries were prepared from each sample using the KAPA Hyper Prep Kit (KAPA Biosystems, Cape Town, South Africa) and exome capture and indexing (SeqCap EZ Exome þ UTR Enrichment Kit, Roche NimbleGen, Madison, WI), all according to manufacturer instructions. Whole-exome libraries were paired-end sequenced using a HiSeq 4000 sequencer (Illumina, San Diego, CA) with a 75 bp read length. Read mapping and variant calling were performed as described previously (8) .
Variant Identification
Results were analyzed using the BasePlayer visualization tool (9) . Variants were filtered by excluding synonymous and noncoding variants and only allowing variants with a minimum coverage of 6 reads and a minimum allelic fraction of 15%. Nonsynonymous variants with an allele frequency <0.001 were allowed, and were compared with the variant databases of the Exome Aggregation Consortium (ExAC) (10) and the Sequencing Initiative Suomi (SISu) project [Institute for Molecular Medicine Finland, University of Helsinki, Finland (http://sisuproject.fi), v4.1, accessed November 30, 2016.] . In order to rank and evaluate the potential pathogenicity of missense variants, we scored the variants using the PROVEAN (11), SIFT (12), PolyPhen (13), and M-CAP (14) variant prediction tools.
Validation of Exome Sequencing by Sanger Sequencing
DNA was extracted as previously described (7) from FFPE sections of the first glioblastoma, the second glioblastoma and normal liver tissue from the patient. Sanger sequencing was carried out to validate the alterations in ALKBH8, CDK10, DVL3, RTTN, SETD1B, and MSH6 that emerged from exome sequencing. PCR products were subjected to direct sequencing on an ABI PRISM 3100 DNA sequencer with the ABI PRISM BigDye Terminator Cycle Sequencing Kit, as previously reported (15) . The primer sequences are described in Supplementary Data Table S1 .
Analysis of Microsatellite Instability (MSI)
Fragment analysis was performed on the first and second glioblastomas and a liver sample of this patient on an ABI3730XL genetic analyzer with 600 LIZ size standards. MSI was assessed using mononucleotide repeats T25 repeat in the 3 0 untranslated region of the CASP2 gene (CAT25) and the standard NCI/IICH-HNPCC marker panel (BAT25 and BAT26) as previous described (16) .
MSH6 Immunohistochemistry
The second glioblastoma was analyzed for the presence of MSH6 protein by immunohistochemistry. Paraffin sections were deparaffinized in xylene and rehydrated through graded alcohols. For antigen retrieval, sections were pretreated with Tris-EDTA (pH 9.0) in a microwave oven at 850 W for
RESULTS
IDH Status in 2 Glioblastomas
Sanger sequencing revealed the absence of mutations in the IDH1 and IDH2 genes, indicating that they are both glioblastoma, IDH-wildtype (17) .
Exome Sequencing and Bioinformatics Analysis
Somatic Variants
In the second glioblastoma, 1091 tumor-specific nonsynonymous single nucleotide variations (SNVs) and indels were identified by exome sequencing. The PROVEAN and SIFT tools predicted 393 missense variants to be damaging. These 393 missense variants, along with all 120 frameshift, splice-site, and nonsense variants, were individually evaluated on the basis of read quality and relevance to the case. The resulting shortlist of tumor-specific variants in 10 genes was further evaluated using the PolyPhen and M-CAP prediction tools (Table 1) .
Germline Variants
Exome sequencing of the normal tissue revealed 359 variants. Of these, 34 were frameshift, splice-site or nonsense variants, and 75 missense variants were predicted by both PROVEAN and SIFT to be damaging. Further evaluation of each of these 109 variants resulted in a shortlist of 6 variants present in both the normal liver and the second glioblastoma tissues, suggesting that these variants are germline mutations (Table 2) .
Validation by Sanger Sequencing
Germline Mutations
Sanger sequencing confirmed the ALKBH8, CDK10, DVL3, RTTN, SETD1B, and MSH6 mutations detected by exome sequencing. As expected, these alterations were present in the normal liver tissue, the first glioblastoma and the second glioblastoma. All of these germline mutations were heterozygous.
Germline and Somatic MSH6 Mutations in the 2 Glioblastomas
Because MSH6 is a DNA repair gene, and therefore of particular interest, we carried out more detailed analyses of the MSH6 mutations. In the first glioblastoma, the germline MSH6 mutation [exon 5; c.3305_3306insT; p.1102-fsinsT(Gly1105/TrpfsX3)] was homozygous, signifying loss of the wild-type allele. In the second glioblastoma, this germline MSH6 mutation was heterozygous, suggesting retention of the wild-type allele. Further sequencing revealed a somatic MSH6 mutation (exon 4; c.1403G>A; p.Arg468His) in the second glioblastoma, but not in the first glioblastoma or in the patient's normal liver tissue (Fig. 1) .
MSI
First glioblastoma, second glioblastoma, and normal liver tissue of this patient as well as 5 negative-control blood and kidney DNA samples from unrelated healthy individuals showed normal ranges of the PCR product sizes in 3 markers, CAT25, BAT25, and BAT26 (18) . Positive controls (i.e. colon cancer cells carrying a MSH2 homozygous mutation and prostate cancer cells carrying a MLH1 homozygous mutation) showed PCR products 10 bp shorter than the normal ranges in all 3 markers, indicating high levels of MSI.
MSH6 Immunohistochemistry
MSH6 immunohistochemistry in the second glioblastoma revealed the absence of MSH6 nuclear immunoreactivity in neoplastic cells with irregular nuclei, but the presence of immunoreactivity in nonneoplastic endothelial cells.
DISCUSSION
MSH6 is a member of the mismatch repair (MMR) family of genes, which recognize and repair base insertions, deletions and misincorporations that can occur during DNA replication and genetic recombination (19) . The present study identified a germline mutation [c.3305_3306insT; p.1102-fsinsT(Gly1105/TrpfsX3)] in the MSH6 mismatch repair gene in an unusual patient who survived from a first glioblastoma and then developed a second glioblastoma 10 years later. This germline MSH6 mutation affects the ATPase domain of the MSH6 protein, which plays a pivotal role in mismatch repair functions, especially in the formation of a sliding clamp (20) . The mutation was a single base-pair insertion leading to a stop codon at codon 1107 (GAT ! TGA; Asp1107*) and consequent protein truncation.
The germline MSH6 mutation in the first glioblastoma was homozygous, suggesting loss of the wild-type allele. The second glioblastoma carried the same germline MSH6 mutation heterozygously, plus a heterozygous somatic MSH6 mutation (c.1403G>A; p.Arg468His) in the mismatch binding domain, which plays a central role in mismatch repair functions, especially DNA recognition (20) . Thus, the first and second glioblastoma both had 2 hits in the MSH6 gene, suggesting that loss of MSH6 function was essential for the development of these lesions.
Somatic MSH6 mutations are largely absent in untreated sporadic glioblastomas, but appear to be common in glioblastomas treated by TMZ (21-23). Cahill et al (21) reported MSH6 mutations and loss of MSH6 protein expression in 3 of 14 (21%) recurrent glioblastomas after treatment with TMZ. There is also evidence that MSH6 mutations are associated with chemoresistance in recurrent glioblastomas (21) (22) (23) . Yip et al (22) demonstrated that knockdown of MSH6 in U251 glioblastoma cells increased resistance to TMZ cytotoxicity. It is of interest to note that the patient in the present study was treated with only radiotherapy (without chemotherapy) after resection of the first glioblastoma.
As with other MMR genes (MLH1, MSH2, PMS2), germline loss of MSH6 is associated with some inherited tumor syndromes, including Turcot syndrome type 1, which is characterized by colorectal cancer and malignant gliomas (24) ; constitutional MMR deficiency (CMMRD) syndrome, characterized by pediatric hematological and brain tumors (high-grade glioma, primitive neuroectodermal tumor/medulloblastoma) and early-onset colorectal cancer (25, 26) ; both of these being autosomal recessive. Furthermore, Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPCC) is caused by an autosomal dominant mutation in MSH6. Lynch syndrome is associated with increased risk of colorectal cancer and other neoplasms, including brain tumors (mostly glioblastoma) (27) (28) (29) . It is of interest to note that the patient in the present study did not present tumors other than glioblastoma, and did not have a family history suggestive of an inherited tumor syndrome. This supports the observations that heterozygous MSH6 mutations may have incomplete penetrance and a later age of tumor onset (30) .
Bouffet et al (31) reported that the number of mutations per tumor exome in CMMRD glioblastomas is significantly higher than in sporadic adult glioblastomas (17 740 vs 40). Other CMMRD tumors, including primitive neuroectodermal tumor, medulloblastoma, gastrointestinal cancers, and leukemia/lymphoma were also hypermutated, with a mean number of 1589 variants (31) . In the present study, the second glioblastoma was shown to harbor 1091 SNVs and indel variants, after germline variants and variants at 0.001 allele frequency from the ExAC and SISu databases were filtered out. Similarly, according to our in-house data, microsatellite-unstable and microsatellite-stable colorectal cancers show a mutational load (postfiltering) of 1000 and 80 variants, respectively (unpublished data). Thus, the number of somatic mutations in the glioblastoma in the present study is compatible with an underlying process of genetic instability. MSH6 mutations in sporadic glioblastomas have also been reported to be associated with a hypermutation phenotype (23) . Sequencing of the kinase domains of 518 protein kinases, Hunter et al (23) observed 2 glioblastomas with unusually large numbers of somatic mutations. These glioblastomas were recurrent after treatment with TMZ, and both carried a MSH6 mutation (23) .
We have previously shown the absence of MSI in the present patient (1), which was confirmed in the present study by additional MSI analysis with higher sensitivity. This is consistent with previous observations that more than 50% of HNPCC with MSH6 mutation displayed a microsatellite stable or low pattern of MSI, in contrast to the findings that almost all HNPCC carrying MLH1 or MSH2 mutations showed high levels of MSI (32, 33) . This may be explained as follows: MSH6 forms a heterodimer with MSH2 (MutSa), which leads to recognition of single-base mismatches and small insertion/ deletion loops, in contrast to heterodimer MutSb formed by MSH2 and MSH3, which recognizes larger insertion/deletion loops (34, 35) . Loss of MSH6 may not lead to larger insertion/ deletion, recognizable by MSI analyses. The patient in the present study survived 10 years after the diagnosis of the first glioblastoma, which is very unusual. The survival of the vast majority of glioblastoma patients is very poor; the median overall survival is 14-16 months with current treatment with surgery, radiotherapy, and chemotherapy (2) (3) (4) . It is of interest to note that the survival of patients with glioblastoma in the setting of Turcot syndrome type 1 with DNA mismatch repair gene mutations is often remarkably long compared with that of patients with sporadic glioblastoma (24) . Loss of MSH6 expression has been associated with longer overall survival in high-grade astrocytoma patients treated with radiotherapy alone, whereas no difference was found in patients who received radiotherapy plus chemotherapy (36) . The molecular mechanisms underlying the association between deregulation of mismatch repair and a more favorable prognosis of brain tumors remain enigmatic. As previously speculated by the Cancer Genome Atlas (TCGA) researchers, there is a subset of individuals with glioblastoma who survive past 3 years. No specific molecular features have yet been associated with long-term survival, but the TCGA study reported decreased frequencies of CDK4 and EGFR amplifications, as well as of CDKN2A deletions, in long-term survivors (37) .
In addition to germline MSH6 mutations, the patient in this study carried germline mutations of several other candidate genes: ALKBH8 (c.1432T>C; p.Thr478Ala), CDK10 (c.878C>T; p.Ser293Leu), DVL3 (c.746C>T; p.Thr249Met), RTTN (c.5900A>C; p.Met1967Arg), and SETD1B (c.4954C>G; p.Arg1652Gly). These mutations are also found in the healthy Finnish population, albeit with low frequency (Table 2 ). It is possible that some of these variants contributed to the observed phenotype or cooperated with loss of MSH6. However, the mutational loss of MSH6 function is a likely main factor, explaining the susceptibility to development of glioblastomas in this unusual patient.
In summary, by performing next-generation sequencing on archival specimens, we have uncovered a molecular background of this rare case. This study emphasizes the potential role of MSH6 in glioblastoma development in the absence of a family history of cancer, as well as the power of sequencing technologies to elucidate the basis of unusual disease phenotypes using decades-old archival tissue specimens.
